
GMO algae: a future raw material for industry
The algae that live in rivers and the sea have been the focus of a great deal of attention in recent years. Whether micro, macro, green, brown, red… they are currently at the heart of an industrial development project for which the European Commission is active. These GMO algae could be deregulated if the European Commission’s July 2023 proposal were to be approved, as they will undergo genetic modification to be transformed into production facilities for pharmaceuticals, cosmetics, food and agrofuels. This article is a first dive into a world that has gone unnoticed until now.

Synthetic Biology, talks are involving GMOs
For the past fifteen years, governments have been discussing “synthetic biology” on an international level. If to date, an “operational” definition exists, the outlines of this field remain hard to draw. Are talks of “synthetic biology” simply a change of semantics, or a genuinely new frontier of the biotechnology field? For the moment, examples of organisms or molecules obtained by synthetic biology are accumulating: unnatural proteins, GMO plants, GMO bacteria, recreated viruses, modification of living organisms directly in the environment, GMO insects, xenobacteria…

GMO viruses as laboratory tools to be spread in the environment ?
In a recent article, researchers detail several ongoing projects for the genetic modification of viruses. Some of these could be deliberately released into the environment. On February 7, 2024, the European Parliament asked the European Commission to study the potential deregulation of these GMO viruses. A general overview of those projects seems therefore necessary.

A Dutch seed company faces up to KWS patents
Inf’OGM interviewed a Dutch seed company that has developed a cold-resistant “organic” maize and that feels threatened by KWS patents. She tells us the story of her company Nordic Maize breeding, of her certified organic maize, of its likely future contamination by GMOs/NGTs…

Prophetic but misleading: fictitious examples in patents

The biotech industry: political pressure
